The update included background on the relationship between GLP-1 receptor agonists and endoscopic procedures, followed by clinical strategies for patients taking these medications.
Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal.
The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal.